- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01404338
Assessment for Tachyphylaxis to Topical Corticosteroids in the Treatment of Psoriasis (Tachyphylaxis)
July 27, 2011 updated by: Patel, Rita Vikram, M.D.
An Investigator-Initiated, Double-Blind, Vehicle-Controlled Study: Assessment for Tachyphylaxis to Topical Corticosteroids in the Treatment of Psoriasis
Tachyphylaxis occurs when a medication is applied multiple times and a decreased response takes place.
Many dermatologists believe that tachyphylaxis to topical steroids commonly occur.
Other believe that tachyphylaxis can be explain by patient non-compliance with topical medications.
This study is looking to prove or disprove the phenomenon of tachyphylaxis by using topical steroids in the psoriasis patient population.
The investigators are looking to enroll 10 patients with symmetric, bilateral, and small psoriasis plaques.
The investigators will either apply a strong topical steroid or a vehicle ointment to the plaques, which is be occluded with a band aid for a one week period.
Weekly, the investigators will inspect the plaques for tachyphylaxis.
This regimen will be repeated during phase 2, to see if there is change in the time to tachyphylaxis.
This regimen will be repeated during phase 3, however, both plaques will be treated with steroid in this phase, and time to tachyphylaxis will be measured.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects must be at least 18 years of age and in good general health as confirmed by a medical history.
- Females of childbearing potential must have a negative urine pregnancy test on Baseline/Week 0 and must agree to use adequate birth control methods during the entire study (a barrier method i.e. condoms, diaphragm; hormonal contraceptives i.e. birth control pills, implants, or injections; intrauterine device, or abstinence).
- Subjects must be diagnosed with stable plaque psoriasis affecting 1% to 10% body surface area (excluding the face, scalp, groin, axillae or other intertriginous areas).
- Subjects receiving phototherapy for their psoriasis.
- Subjects must have at least two symmetrical lesions suitable for evaluating response to test agents (one on the right side and one on the left side of the body). The severity of the disease for each target lesion at Baseline/Week 0 must be rated at least 2 (Mild) for each of the key psoriasis characteristics (scaling, erythema, and plaque elevation) on the Target Lesion Severity Score.
- Subjects must be able to understand the requirements of the study abide by the restrictions and return for the required examinations.
Exclusion Criteria:
- Female subjects who are pregnant, nursing or planning a pregnancy during the study.
- Subjects with known hypersensitivity to any components of the test medication.
- Subjects with non-plaque psoriasis (e.g. guttate, erythrodermic) or other related diseases not classified as plaque psoriasis.
- Subjects whose psoriasis involves only the scalp, face, groin, axillae, and/or other intertriginous areas.
- Subjects requiring any other medication (topical or systemic) that may affect the course of the disease during the study period as determined by the study investigators.
- Subjects using biologics or any other systemic treatment (e.g. immunosuppressants, acitretin) for psoriasis within 12 weeks of entering the study.
- Subjects using systemic corticosteroids within 28 days of entering the study
- Subjects using topical corticosteroids or other topical therapies (other than emollients) at the treatment area locations within 14 days of entering the study
- Subjects using phototherapy (UVB, PUVA) on target treatment sites within 4 weeks of entering the study.
- Subjects with overt pre-existing telangiectasias or skin atrophy at intended treatment sites (treatment areas).
- Subjects who are using any medication or has any disease which in the judgment of the investigator will interfere with the conduct or interpretation of the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active Arm
1. Active arm/Target Lesion: Halobetasol 0.05% ointment applied under occlusion to be left in place for one week
|
|
Placebo Comparator: Vehicle Arm
Vehicle arm/Comparator Lesion: Vehicle ointment applied under occlusion to be left in place for one week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Tachyphylaxis
Time Frame: 4 Weeks
|
Phase 1: %change in TLSS of target lesion versus comparator lesion Phase 2a, after an interim discontinuation period of 4-8 weeks: %change in TLSS of target lesion versus comparator lesion Phase 2b, after an interim discontinuation period of 4-8 weeks: Percent change in TLSS of the comparator lesion (now switched to open-label halobetasol 0.05% ointment) versus target lesion
|
4 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2011
Study Registration Dates
First Submitted
July 25, 2011
First Submitted That Met QC Criteria
July 27, 2011
First Posted (Estimate)
July 28, 2011
Study Record Updates
Last Update Posted (Estimate)
July 28, 2011
Last Update Submitted That Met QC Criteria
July 27, 2011
Last Verified
July 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-0422
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis
-
ProgenaBiomeRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Face | Psoriasis Nail | Psoriasis Diffusa | Psoriasis Punctata | Psoriasis Palmaris | Psoriasis Circinata | Psoriasis Annularis | Psoriasis Genital | Psoriasis GeographicaUnited States
-
Clin4allRecruitingPsoriasis of Scalp | Psoriasis Nail | Psoriasis Palmaris | Psoriasis Genital | Psoriasis PlantarisFrance
-
Innovaderm Research Inc.CompletedScalp Psoriasis | Pustular Palmo-plantar Psoriasis | Non-pustular Palmo-plantar Psoriasis | Elbow Psoriasis | Lower Leg PsoriasisCanada
-
Centre of Evidence of the French Society of DermatologyRecruitingPsoriasis | Psoriasis Vulgaris | Psoriasis of Scalp | Psoriatic Plaque | Psoriasis Universalis | Psoriasis Palmaris | Psoriatic Erythroderma | Psoriatic Nail | Psoriasis Guttate | Psoriasis Inverse | Psoriasis PustularFrance
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
AmgenCompletedPsoriasis-Type Psoriasis | Plaque-Type PsoriasisUnited States
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Eli Lilly and CompanyCompletedGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
TakedaRecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
Herlev and Gentofte HospitalRecruitingMyocardial Infarction | Myocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Heart Failure | Stroke | Psoriasis | Heart Failure, Diastolic | Psoriasis Vulgaris | Cardiovascular Risk Factor | Heart Failure, Systolic | Left Ventricular Dysfunction | Psoriasis Universalis | Psoriasis Face | Psoriasis Diffusa | Psoriasis... and other conditionsDenmark
Clinical Trials on Halobetasol 0.05% ointment
-
Icahn School of Medicine at Mount SinaiCompleted
-
Actavis Inc.Completed
-
Padagis LLCCompleted
-
Actavis Inc.Completed
-
Padagis LLCCompleted
-
Therapeutics, Inc.CompletedPlaque PsoriasisUnited States
-
Therapeutics, Inc.CompletedPsoriasis | Plaque PsoriasisUnited States
-
Sun Pharmaceutical Industries LimitedNovum Pharmaceutical Research ServicesTerminated
-
Skin Sciences, PLLCUnknownPlaque PsoriasisUnited States
-
Sun Pharmaceutical Industries LimitedTerminatedPlaque PsoriasisUnited States